In persistent diabetic macular edema, 22% of eyes gained at least two vision lines.
Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
Rita Ehrlich … Itay Chowers
European journal of ophthalmology · 2019
Purpose
: To evaluate the outcome of second-line intravitreal ranibizumab treatment in eyes with diabetic macular edema having persistent edema following initial therapy with intravitreal bevacizumab.
Methods
: Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel was a retrospective, multi-center study.
n = 202 eyes
22%
Results
22%
eyes gained at least two lines of vision, meaning better eyesight
n = 202 eyes
More results
Patients received a mean (±standard deviation) of 8.8 ± 4.9 intravitreal bevacizumab injections prior to the switch to intravitreal ranibizumab.
A mean of 7.0 ± 2.7 intravitreal ranibizumab injections were given during the 12 months following the switch to intravitreal ranibizumab.
More results
The median central subfield retinal thickness (±interquartile range) by spectral-domain optical coherence tomography decreased from 436 ± 162 µm at baseline to 319 ± 113 µm at month 12 (p < 0.001).
Median logMAR visual acuity (±interquartile range) improved from 0.40 ± 0.48 at baseline to 0.38 ± 0.40 at month 12 (p = 0.001).
“
Conclusion
: Switching from bevacizumab to ranibizumab in persistent diabetic macular edema was associated with anatomical improvement in the majority of eyes and ⩾2 lines of vision improvement in 22% of eyes.
